News Center
20
2023-12
2023-12-20
InxMed Enters License Agreement with Escugen to Develop Next-Generation ADCs
25
2023-10
2023-10-25
InxMed Releases Data Demonstrating Ifebemtinib (IN10018) Trending Toward Survival Benefit at ESMO 2023
19
2023-10
2023-10-19
InxMed Presents New Data at 14th Annual World ADC Highlighting Synergy of IN10018 with ADCs and Novel Stroma targeting pipeline
30
2023-08
2023-08-30
InxMed Receives Approval to Initiate Phase I Clinical Trial in China for OMTX705, a First-in-Class FAP-Targeting ADC
18
2022-10
2022-10-18
InxMed Releases Data Demonstrating IN10018 Therapeutic Potential in Patients with Metastatic Melanoma at SMR 2022
08
2022-09
2022-09-08
InxMed Announces First Patient Dosed in Pivotal Phase 2 Study of IN10018 In Patients with Platinum-Resistant Recurrent Ovarian Cancer
Previous
1
2
…
4
Next
We invent personalized medicines with global impact, and turn innovation in China to life saving therapies for the world
QUICK LINKS
CONTACT US
Tel: +86 25-58251030
Email: office@inxmed.com
Office address: 73 Tanmi Road Block D-2, 3rd Floor Jiangbei New District, Nanjing
MESSAGE
Follow Us:
CopyRight © 2022 InxMed All Rights Reserved.